Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
出版年份 2018 全文链接
标题
Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
作者
关键词
Immune-related adverse events, Immune checkpoint inhibitor, Organ specialists, Corticosteroid, Immunomodulatory/immunosuppressive agents
出版物
International Journal of Clinical Oncology
Volume 23, Issue 3, Pages 410-420
出版商
Springer Nature
发表日期
2018-03-07
DOI
10.1007/s10147-018-1259-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient
- (2015) Elisabetta Miserocchi et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
- (2015) Caroline Gaudy et al. DIABETES CARE
- Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis
- (2015) Andreas Kronbichler et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Future Oncology
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-induced toxicities and the gastroenterologist
- (2015) Robert Cheng et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Peripheral Neuropathy Associated With Ipilimumab
- (2015) Iyavut Thaipisuttikul et al. JOURNAL OF IMMUNOTHERAPY
- Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
- (2015) Matthew M. K. Chan et al. JOURNAL OF IMMUNOTHERAPY
- Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer
- (2015) Aaron I. Loochtan et al. MUSCLE & NERVE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
- (2015) A Doran Bostwick et al. Journal for ImmunoTherapy of Cancer
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome
- (2015) Benjamin P Geisler et al. Journal for ImmunoTherapy of Cancer
- Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
- (2014) Gary Hunter et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
- (2014) Magnus Pedersen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Kidney injuries related to ipilimumab
- (2014) Hassane Izzedine et al. INVESTIGATIONAL NEW DRUGS
- Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma
- (2014) Pauline du Rusquec et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab in patients with melanoma and autoimmune disease
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
- (2013) Igor Z. Barjaktarevic et al. CHEST
- The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
- (2013) Kira Minkis et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Association Between Ipilimumab and Celiac Disease
- (2013) Nicole M. Gentile et al. MAYO CLINIC PROCEEDINGS
- Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
- (2012) David E. Kleiner et al. DIGESTIVE DISEASES AND SCIENCES
- Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
- (2012) Grégoire Berthod et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti–Cytotoxic T-Cell Lymphocyte Antigen-4–Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss
- (2012) Caroline Voskens et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- A Severe Case of Ipilimumab-Induced Guillain-Barré Syndrome Revealed by an Occlusive Enteric Neuropathy
- (2012) Caroline Gaudy-Marqueste et al. JOURNAL OF IMMUNOTHERAPY
- Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
- (2012) Sebastian G. Bernardo et al. MELANOMA RESEARCH
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma
- (2011) S Ahmad et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
- (2009) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
- (2009) Mojtaba Akhtari et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
- (2008) J. D. Wolchok et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started